Therefore, our data suggest that small molecules that block SFPQ/DNA interactions or protein degraders93 that target SFPQ for proteasomal turnover could be intriguing therapeutic approaches across EBV-associated lymphomas and carcinomas, which collectively represent 1% of human cancer2. The gene discussed is SFPQ; the disease is carcinoma.